

## DAFTAR PUSTAKA

1. Popkin BM, D'Anci KE, Rosenberg IH. Water, hydration, and health. *Nutr Rev.* 2010;68(8):439–58.
2. Kurniati ID, Notoatmojo H, Putra DPY. Kualitas Fisik dan Sumber Air yang Dikonsumsi Berpengaruh Terhadap Kejadian Diare pada Balita. [Http://DigilibUnimusAcId1](http://DigilibUnimusAcId1) [Internet]. 2013;1–5. Available from: <http://digilib.unimus.ac.id>
3. Bartram J, Ballance R. *Water Quality Monitoring - A Practical Guide to the Design and Implementation of Freshwater Quality Studies and Monitoring Programmes.* UNEP/WHO. 2012;
4. Nick gray C gleeson. *The Coliform Index and Waterborne Disease.* E & FN SPON. 2013.
5. Sweileh WM, Zyoud SH, Al-Jabi SW, Sawalha AF, Shraim NY. Drinking and recreational water-related diseases: A bibliometric analysis (1980-2015). *Ann Occup Environ Med* [Internet]. 2016;28(1):1–11. Available from: <http://dx.doi.org/10.1186/s40557-016-0128-x>
6. Humayun E, Bibi A, Rehman AU, Ahmad S, Shujaat N. Isolation and Identification of Coliform Bacteria from Drinking Water Sources of Hazara Division , Pakistan. 2015;5(4):36–40.
7. Khoeriyah A, Anies. Aspek Kualitas Bakteriologis Depot Air Minum Isi Ulang (DAMIU) di Kabupaten Bandung Barat. *Maj Kedokt Bandung.* 2015;47(3):137–44.
8. Anam C, Mahmudati N, Hudha AM. Kualitas Mikrobiologi Air Sumur Berdasarkan Total Koliform Di Kabupaten Trenggalek. *Pendidik Mat dan Ilmu Pengetah Alam.* 2016;(1):1019–28.
9. Yogafanny E, Fuchs S, Obst U. Study of Slow Sand Filtration in Removing Total Coliforms and E.Coli. *J Sains &Teknologi Lingkungan.* 2014;6(2):107–16.
10. Maurya A, Singh MK, Kumar S. Biofiltration technique for removal of waterborne pathogens. *Waterborne Pathog.* 2020;(January):123–41.
11. Permenkes No. 492/Th.2010. Persyaratan Kualitas Air Minum. Peraturan Menteri Kesehatan Republik Indonesia. 2010.
12. Ramírez-Castillo FY, Loera-Muro A, Jacques M, Garneau P, Avelar-González FJ, Harel J, et al. Waterborne pathogens: Detection methods and challenges. *Pathogens.* 2015;4(2):307–34.

13. Riley, M.R., Gerba, C.P., Elimelech M. Biological approaches for addressing the grand challenge of providing access to clean drinking water. 2011;
14. Bridle H. Overview of waterborne pathogens. 2013;(In: Waterborne Pathogens: Detection Methods and Applications):9–40.
15. Leclerc, H., Schwartzbrod, L., Dei-Cas E. Microbial agents associated with waterborne diseases. 2002;(Crit. Rev. Microbiol).
16. Hrudey SE HE. Safe drinking water. London: International Water Association Publishing; 2004.
17. Blasi M. Water-related diseases outbreaks reported in Italy. 2008. 6:423–432.
18. Craun M. Waterborne outbreaks reported in the United States. 2006. 4:19–30.
19. Beaudreau P. Lessons learned from ten investigations of waterborne gastroenteritis outbreaks. France; 2008. 6:491–503.
20. Agency HP. Communicable disease and health protection quarterly review. 2008. 30:510–511.
21. Bitton G. Microbiology of Drinking Water Production and Distribution. 1st ed. NJ, USA: John Wiley & Sons, Inc.; 2014. 312 p.
22. Ingerson-Mahar M. RA. Microbes in Pipes: The Microbiology of the Water Distribution System A Report on an American Academy of Microbiology Colloquium. CO, USA: ASM Academy; 2012. 26 p.
23. Alhamlan F.S., Al-Qahtani A.A. A-AM. Recommended advanced techniques for waterborne pathogen detection in developing countries. 2015. 9:128–135.
24. WHO. Progress on Sanitation and Drinking-Water. Geneva, Switzerland: World Health Organization (WHO); 2010.
25. Pandey P.K., Kass P.H., Soupir M.L., Biswas S. SV. Contamination of water resources by pathogenic bacteria. AMB Express; 2014. 4:51.
26. WHO. Millennium Development Goals: Progress towards the Health-Related Millennium Development Goals. Geneva, Switzerland: World Health Organization (WHO); 2010.
27. Committee WP, Pathogens W, Isbn C, Pdf T, Press NA, Press NA, et al. Indicators for Waterborne Pathogens. Indicators for Waterborne Pathogens. 2004.

28. WHO. Water quality for drinking: who guidelines. SpringerReference. 2011;4th editio.
29. Magana-Arachchi DN, Wanigatunge RP. Ubiquitous waterborne pathogens. *Waterborne Pathog.* 2020;(January):15–42.
30. Tindall BJ, Grimont PA, Garrity GM EJ. Nomenclature and taxonomy of the genus *Salmonella*. *Int J Syst Evol Microbiol.* 2005;55:521–524.
31. Giannella R. *Salmonella*. Baron S, editor. Galveston, TX: University of Texas Medical Branch at Galveston; 2010. Chapter 21.
32. Strockbine M. *Bergey's Manual of Systematic Bacteriology.* 2005. 811–823 p.
33. Jeong H. J., Jang E. S. HBI. *Acanthamoeba*: could it be an environmental host of *Shigella*? *Experimental Parasitology.* 2007;115(2):181–186.
34. Zhang W, Luo Y, Li J, Lin L, Ma Y HC. Wide dissemination of multidrug-resistant *Shigella* isolates in China. *J Antimicrob Chemother.* 2011;66:2527–2535.
35. Sansonetti PJ, Hale TL, Dammin GJ, Kapfer C, Collins HH, Jr. FS. Alterations in the pathogenicity of *Escherichia coli* K-12 after transfer of plasmid and chromosomal genes from *Shigella flexneri*. 2004;39:1392–1402.
36. Sansonetti PJ, Kopecko DJ FS. Involvement of a plasmid in the invasive ability of *Shigella flexneri*. 2011;35:852–860.
37. Buchrieser C, Glaser P, Rusniok C, Nedjari H, D'Hauteville H KF. The virulence plasmid pWR100 and the repertoire of proteins secreted by the type III secretion apparatus of *Shigella flexneri*. 2010;38:760–771.
38. Le Gall T, Mavris M, Martino MC, Bernardini ML, Denamur E PC. Analysis of virulence plasmid gene expression defines three classes of effectors in the type III secretion system of *Shigella flexneri*. 2005;151:951–962.
39. Fasano A, Noriega FR, Liao FM, Wang W LM. Effect of *Shigella* enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivo. 2007;40:505–511.
40. Farfan MJ, Toro CS, Barry EM NJ. *Shigella* enterotoxin-2 is a type III effector that participates in *Shigella*-induced interleukin 8 secretion by epithelial cells. *FEMS Immunol.* 2011;61:332–339.
41. Acke E. *Campylobacteriosis* in dogs and cats: a review. *N. Z. Vet. J.* 2018;66(5):221–228.

42. Hsieh Y.-H. SI. Chapter 5 - campylobacteriosis: an emerging infectious foodborne disease. Holban A.M. 2018. 119–155 p.
43. Pal M. Campylobacter jejuni: an emerging foodborne pathogen of global significance. *J Exp Food Chem.* 2017;3(3):1–4.
44. Frirdich E., Biboy J., Huynh S., Parker C.T., Vollmer W. GE. Morphology heterogeneity within a Campylobacter jejuni helical population: the use of calcofluor white to generate rod-shaped C. jejuni 81-176 clones and the genetic determinants responsible for differences in morphology within 11168 strains. *Mol Microbiol.* 2017;104(6):948–97.
45. Tribble D.R., Baqar S., Scott D.A., Oplinger M.L., Trespalacios F., Rollins D., Walker R.I., Clements J.D., Walz S., Gibbs P., Burg E.F.I., Moran A.P., Applebee L. BA. Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans. *Infect Immun.* 2010;78(4)(1750–1759).
46. A.M A. A case of bacteremia caused by Campylobacter fetus: an unusual presentation in an infant. *Infect Drug Resist.* 2014;7:37–40.
47. Morishita S., Fujiwara H., Murota H., Maeda Y., Hara A. HT. Bloodstream infection caused by Campylobacter lari. *J Infect Chemother.* 2013;19(2):333–337.
48. Lagler H., Kiesewetter B. RM. Infection with multidrug-resistant Campylobacter coli mimicking recurrence of carcinoid syndrome: a case report of a neuroendocrine tumor patient with repeated diarrhea. *BMC Infect Dis.* 2016;16:409.
49. Man S. The clinical importance of emerging Campylobacter species. 2011;8(12):669–685.
50. Grant A.J., Maskell D.J. HM. Phylogenetic Analyses and Antimicrobial Resistance Profiles of Campylobacter Spp. From Diarrhoea Patients and Chickens in Botswana. 2018;
51. Mungai E.A., Behraves C.B. GL. Increased outbreaks associated with nonpasteurized milk. 2015;21(1):119–122.
52. Larson C.L., Shah D.H. DA. Campylobacter jejuni invade chicken LMH cells inefficiently and stimulate differential expression of the chicken CXCLi1 and CXCLi2 cytokines. *Microbiology.* 2008;154:3835–3847.
53. Casabonne C., Gonzalez A., Aquili V., Subils T. BC. Prevalence of seven virulence genes of Campylobacter jejuni isolated from patients with diarrhea in Rosario, Argentina. *Int J Infect.* 2016;3(4):1–6.

54. Bhavsar S. KB. Virulence factors of *Campylobacter*. 2006;3(2):1–7.
55. Backert S., Boehm M., Wessler S. TN. Transmigration route of *Campylobacter jejuni* across polarized intestinal epithelial cells: paracellular, transcellular or both? 2013;11(1):72.
56. Biswas D., Hannon S.H., Townsend G.G.H., Potter A. AB. Genes coding for virulence determinants of *Campylobacter jejuni* in human clinical and cattle isolates from Alberta, Canada, and their potential role in colonization of poultry. 2011;14(1):25–32.
57. Asakura M., Samosornsuk W., Hinenoya A., Misawa N., Nishimura K., Matsuhisa A. YS. Development of a cytolethal distending toxin (cdt) gene-based species-specific multiplex PCR assay for the detection and identification of *Campylobacter jejuni*, *Campylobacter coli* and *Campylobacter fetus*. FEMS Immunol Med Microbiol. 2008;52:260–266.
58. Abuoun M., Manning G., Cawthraw S.A., Ridley A., Ahmed I.H., Wassenaar T.M. ND. Cytolethal distending toxin (CDT)-negative *Campylobacter jejuni* strains and anti-CDT neutralizing antibodies are induced during human infection but not during colonization in chickens. 2005;73(5):73(5).
59. Carvalho A.F.D., Silva D.M.D., Azevedo S.S., Piatti R.M., Genovez M.E. SE. Detection of CDT toxin genes in *Campylobacter* spp. strains isolated from broiler carcasses and vegetables in São Paulo, Brazil. Braz J Microbiol. 2013;44(3):693–699.
60. Makvana S, Krilov LR. *Escherichia coli* Infections. *Pediatr Rev*. 2015;36(4):167–71.
61. Edwards PR and Ewing W. *Identification of Enterobacteriaceae* (3rd ed.). Minnesota, USA: Burgess Publishing Co; 2012.
62. Chaudhary S, Khurana S, Mane B. *Escherichia coli*: Animal Foods and Public Health-Review. *J Microbiol Immunol Biotechnol* [Internet]. 2014;1(December 2014):31–46. Available from: [http://jakraya.com/journal/pdf/2-jmibArticle\\_4.pdf](http://jakraya.com/journal/pdf/2-jmibArticle_4.pdf)
63. Fazeli H, Akbari R, Moghim S, Narimani T, Arabestani MR GA. *Pseudomonas aeruginosa* infections in patients, hospital means, and personnel's specimens. *J Res Med Sci*. 2012;17(4):332–372.
64. Pier GB RR. *Pseudomonas aeruginosa*. G. L. Mand. *Mandell*; 2005.
65. Kollef M. Antibiotics for the critically ill: more than just selecting appropriate initial therapy. 2013;17 (3):146.

66. Gonzalez L, Cravoisy A, Barraud D, Conrad M, Nace L LJ. Factors influencing the implementation of antibiotic deescalation and impact of this strategy in critically ill patients. 2013;4:140.
67. Henkin CS, Coelho JC, Paganella MCI, Siqueira RM DF. Sepsis: uma visão atual. 2009;3:134–45.
68. Alayande AB, Aung MM KI. Correlation Between Quorum Sensing Signal Molecules and *Pseudomonas aeruginosa*'s Biofilm Development and Virulence. 2018. 787–793 p.
69. Rocha AJ, De Oliveira Barsottini MR, Rocha RR, Laurindo MV, De Moraes FLL, Da Rocha SL. *Pseudomonas aeruginosa*: Virulence factors and antibiotic resistance Genes. Brazilian Arch Biol Technol. 2019;62(June):1–15.
70. Mandell G, Bennett J DR. Principles and practice of infectious diseases 7 Th Edition. New York: Elsevier; 2009.
71. Punsalang AP, Sawyer WD. Role of pili in the virulence of *Neisseria gonorrhoeae*. 2003;8(2):255–63.
72. Iglewski, BH, Liu, PV, Kabat D. Mechanism of action of *Pseudomonas aeruginosa* exotoxin A: adenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo. Infect Immun. 2007;1:138–44.
73. Oladokun MO, Okoh IA. *Vibrio cholerae*: A historical perspective and current trend. Asian Pacific J Trop Dis. 2016;6(11):895–908.
74. Kamel FH, Jarjes SF. Essentials of Bacteriology and Immunology. 2016;(January 2015):218.
75. Lesmana M. Perkembangan mutakhir infeksi kolera. J Kedokter Trisakti. 2004;23(3):101–9.
76. Praja RKA, Rosalina R. Molecular Mechanism of *Cholerae* Toxin (ctx) in Causing Diarrhea. Ocean Biomed J. 2018;1(2):116.
77. Brooks, G.F., Carrol, K.C., Butel, J.S., Morse, S.A. and Mietzner T. Medical Microbiology 26th Edition. McGraw-Hill Companies Inc; 2013.
78. Maheshwari, M., Nelapati, K. and Kiranmayi B. *Vibrio cholerae* - A Review. Vet World. 2011;4(9):423–8.
79. Ramazanzadeh, R., Rouhi, S., Shakib, P., Shahbazi, B., Bidarpour, F. and Karimi M. Molecular Characterization of *Vibrio cholerae* Isolated from Clinical Samples in Kurdistan Province, Iran. Jundishapur J Microbiol. 2015;8 (5):1–6.

80. Schild, S., Bishop, A.L. and Camilli A. Ins and outs of *Vibrio cholerae*: *Vibrio cholerae* transitions between the human gut and the aquatic environment are aided by specific shifts in gene expression. 2008;3(3):131±136.
81. Bercovier, H. and Mollaret HH. *Yersinia*: Bergey's Manual of Systematic Bacteriology. Vol. 1. Baltimore: Williams & Wilkins; 2009. 498–506 p.
82. Cornelis, G. R., Boland, A., Boyd AP. The virulence plasmid of *Yersinia*, an antihost genome. *Microbiol Mol Biol*. 2008;62:1315–1352.
83. Bottone E. *Yersinia enterocolitica*: Revisitation of an enduring human pathogen. *Clin Microbiol*. 2015;37:1–8.
84. Wauters, G., Kandolo, K., and Janssens M. Revised biogrouping scheme of *Yersinia enterocolitica*. *Contr Microbiol Immunol*. 2013;9:14–21.
85. Hein J., Volkhard A.J., Kempf J.D., Bücheler N., Preger S., Horak I., Sing A., Kramer U. AI. Interferon consensus sequence binding protein confers resistance against *Yersinia enterocolitica*. 2010;68:1408–1417.
86. Gierczyński R. Evaluation of the usefulness of selected virulence markers for identification of virulent *Yersinia enterocolitica* strains. 2000;52:35–49.
87. Liyanage H.M., Magana Arachchi D.N., Abeysekara T. GL. Toxicology of freshwater cyanobacteria. *J Environ Sci Heal Part C*. 2016;34(3):137–168.
88. Davis T.W., Berry D. L., Boyer G. L. GCJ. The effects of temperature and nutrients on the growth and dynamics of toxic and non-toxic strains of *Microcystis* during cyanobacterial blooms, *Harmful Algae*. 2009;8 (5):715–725.
89. Polyak Y, Zaytseva T, Medvedeva N. Response of toxic cyanobacterium *microcystis aeruginosa* to environmental pollution. *Water Air Soil Pollut*. 2013;224(4).
90. Mazur-Marzec H, Browarczyk-Matusiak G, Forycka K, Kobos J, Pliński M. Morphological, genetic, chemical and ecophysiological characterisation of two *microcystis aeruginosa* isolates from the Vistula Lagoon, southern Baltic. *Oceanologia*. 2010;52(1):127–46.
91. Sivonen K. BT. Bioactive compounds produced by cyanobacteria. Herrero A, Flores & E, editors. Norfolk, U.K: Caister Acad. Press; 2008. 159–197 p.
92. MacKintosh C., Beattie K.A., Klumpp S., Cohen P. CGA. Cyanobacterial microcystin-LR is a potent and specific inhibitor of protein phosphatases 1 and 2A from both mammals and higher plants. 2016;264 (2):187–192.

93. Zurawell R.W., Chen H., Burke J.M. PE. Hepatotoxic cyanobacteria: a review of the biological importance of microcystins in freshwater environments. *J Toxicol Env Heal.* 2005;8 (1):1–37.
94. Funari E. TE. Human health risk assessment related to cyanotoxin exposure. *Crit Rev Toxicol.* 2008;38 (2):97–125.
95. Kurmayer R. CG. The genetic basis of toxin production in Cyanobacteria. 2009;2(1):31–50.
96. Gibson K. Viral pathogens in water: occurrence, public health impact, and available control strategies. 2014;4:50–57.
97. Goldsmith CS, Miller SE. Modern uses of electron microscopy for detection of viruses. *Clin Microbiol Rev.* 2009;22(4):552–63.
98. Tang, J.W.; Nicolle, A.D.; Klettner, C.A.; Pantelic, J.; Wang, L.; Bin Suhaimi, A.; Tan, A.Y.L.; Ong GW. Airflow Dynamics of Human Jets: Sneezing and Breathing-Potential Sources of Infectious Aerosols. 2013;8.
99. Yin-Murphy, M.; Almond J. Chapter 53 Picornaviruses. Galveston ,TX: Univ. of Texas Medical Branch at Galveston; 2016. 1–18 p.
100. Cox, J.A.; Hiscox, J.A.; Solomon T. Immunopathogenesis and Virus–Host Interactions of Enterovirus 71 in Patients with Hand, Foot and Mouth Disease. *Front Microbiol.* 2017;8:2249.
101. WHO. W.H.O. a Guide to Clinical Management and Public Health Response for Hand, Foot and Mouth Disease (HFMD). Manila, Philippines: WHO Regional Office for the Western Pacific; 2011.
102. Fujimoto, T.; Chikahira, M.; Yoshida, S.; Ebira, H.; Hasegawa, A.; Totsuka, A.; Nishio O. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: Detection and molecular epidemiology of enterovirus 71. *Microbiol Immunol.* 2002;46(621–627).
103. Cuthbert JA. Hepatitis A: Old and new. *Clin Microbiol Rev.* 2011;14(1):38–58.
104. Carlsson S. Hepatitis A virus. 2015;1:1.
105. Wheeler CM, Fields HA, Schable CA, Meinke WJ, Maynard JE. Adsorption, purification, and growth characteristics of hepatitis A virus strain HAS-15 propagated in fetal rhesus monkey kidney cells. *J Clin Microbiol.* 2018;23(3):434–40.
106. Walker F., Rudan I., Liu L., Nair H., Theodoratou E., Bhutta A., O’Brien L.,



- Campbell H. BE. Global burden of childhood pneumonia and diarrhoea. 2013;381:1405–1416.
107. Elliott EJ. Acute gastroenteritis in children. *Br Med J*. 2007;334(7583):35–40.
  108. Wang H., Liddell A., Coates M., Mooney D., Levitz E., Schumacher E. MC. Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the global burden of disease study 2013. 2014;384:957–979.
  109. WHO. State of the World’s Vaccines and Immunization. 2009;3.
  110. Crawford SE, Ramani S, Tate JE, Parashar UD, Svensson L, Hagbom M, et al. Rotavirus infection HHS Public Access. *JAMA Pediatr* [Internet]. 2018;172(SUPPL. 3):50–3. Available from: <http://repositorio.uchile.cl/bitstream/handle/2250/148901/Rotavirus-infection.pdf?sequence=1&isAllowed=y>
  111. Schnell MA, Zhang Y, Tazelaar J, Gao GP, Yu QC, Qian R, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. *Mol Ther*. 2011;3(5):708–22.
  112. Jiang C. Human adenoviruses in water: occurrence and health implications: a critical review. *Environ Sci Technol*. 2006;40(23):7132–7140.
  113. Pager T. SD. A1. Pager T. SD. Astrovirus-associated diarrhea in South African adults. *Clin Infect Dis*. 2012;35(11):1452–1453. strovirus-associated diarrhea in South African adults. *Clin Infect Dis*. 2012;35(11):1452–1453.
  114. González G., Pujol H., Liprandi F., Deibis L. LE. Prevalence of enteric viruses in human immunodeficiency virus seropositive patients in Venezuela. *J Med Virol*. 2008;55(4):288–292.
  115. Silva AMV, Leite EG, Assis RMS, Majerowicz S, Leite JPG. An Outbreak of Gastroenteritis Associated with Astrovirus Serotype 1 in a Day Care Center, in Rio de Janeiro, Brazil. *Mem Inst Oswaldo Cruz*. 2014;96(8):1069–73.
  116. Gofti-Laroche L., Gratacap-Cavallier B., Demanse D., Genoulaz O., Seigneurin J. ZD. Are waterborne astrovirus implicated in acute digestive morbidity (E.MI.R.A. study)? *J Clin Virol*. 2013;27(1):74–82.
  117. Pescod MB, Abouzaid H, Sundaresan BB. Slow sand filtration: A low cost Treatment for Water Supplies in Developing Countries. Slow sand Filtr a low cost Treat water supplies Dev Ctries [Internet]. 2016;10–4. Available from: <https://www.ircwash.org/sites/default/files/255.1-85SL-11268.pdf>

118. Verma, Daverey, A., Sharma A. Slow sand filtration for water and wastewater treatment review. *Environ Technol.* 2017;6:47–58.
119. Bauer, R., Dizer, H., Graeber, I., Rosenwinkel, K.H., Lo´pez-Pila J. Removal of bacterial fecal indicators, coliphages and enteric adenoviruses from waters with high fecal pollution by slow sand filtration. *Water Res.* 2011;45:439–52.
120. Hammes, F., Velten, S., Egli, T., Juhna T. *Biotreatment of drinking water*, second ed. Elsevier; 2011.
121. Guchi E. Review on slow sand filtration in removing microbial contamination and particles from drinking water. 2015;3:47–55.
122. Yahya MT, Cluff CB, Gerba CP. Virus removal by slow sand filtration and nanofiltration. *Water Sci Technol.* 2013;27(3–4):445–8.
123. Torii S., Hashimoto T., Do A.T., Furumai H. KH. Impact of repeated pressurization on virus removal by reverse osmosis membranes for household water treatment. *Environ Sci.* 2019;1.
124. Stoica I.M., Vitzilaiou E., Røder H.L., Burmølle M., Thaysen D., Knøchel S. van den BF. Biofouling on RO-membranes used for water recovery in the dairy industry. *J Water Proc Eng.* 2018;24:1–10.
125. Langlet J., Gaboriaud F., Duval J.F.L. GC. Aggregation and surface properties of F-specific RNA phages: implication for membrane filtration processes. *Water Res.* 2008;42:2769–2777.
126. Langlet J., Ogorzaly L., Schrotter J.C., Machinal C., Gaboriaud F., Duval J.F.L. GC. Efficiency of MS2 phage and Q $\beta$  phage removal by membrane filtration in water treatment: applicability of real-time RT-PCR method. *J Membr Sci.* 2009;326:111–116.
127. Bohonak M. ZL. Compaction and permeability effects with virus filtration membranes. *J Membr Sci.* 2005;254:71–79.
128. Luo Y., Guo W., Ngo H.H., Nghiem L.D., Hai F.I., Zhang J., Liang S. WX. A review on the occurrence of micropollutants in the aquatic environment and their fate and removal during wastewater treatment. *Sci Total Env.* 2014;473:619–641.
129. Farrukh MA. *Nanofiltration* Edited by Muhammad Akhyar Farrukh [Internet]. 2018. Available from: <https://www.researchgate.net/publication/326345577>
130. Roy, Yagnaseni; Warsinger, David M.; Lienhard JH. Effect of temperature on ion transport in nanofiltration membranes: Diffusion, convection and

- electromigration. *Desalination*. 2017;420:241–257.
131. Tran T, Nguyen TB, Ho HL, Le DA, Lam TD, Nguyen DC, et al. Integration of membrane bioreactor and nanofiltration for the treatment process of real hospital wastewater in Ho Chi Minh City, Vietnam. *Processes*. 2019;7(3):1–13.
  132. Taylor J., Lovins W.A. CS. Emerging contaminants and membrane technology. *Flo Water Resour J*. 2012;34–45.
  133. Yue C, Teitz S, Miyabashi T, Boller K, Lewis-Ximenez LL, Baylis SA, et al. Inactivation and removal of chikungunya virus and mayaro virus from plasma-derived medicinal products. *Viruses*. 2019;11(3).
  134. CDC. Disinfection with chlorine. *Public Water Syst*. 2018;1.
  135. Ramli N, Navianti D, Karwiti W. Pengaruh Jenis Air Yang Digunakan Terhadap Kadar Klorin Pada Air Seduhan Kertas Pembungkus Teh Celup. *J Heal* [Internet]. 2014;1. Available from: <https://drive.google.com/file/d/0B4De5cC6M0vOMmVpdEVmbUpqUGc/view>
  136. LeChevallier MW. Water Treatment and Pathogen Control: Process Efficiency in Achieving Safe Drinking-water. *Water Intell Online*. 2013;12.
  137. Bitton G. *Wastewater microbiology*, 4th Ed. Hoboken, New Jersey: Wiley-Blackwell, John Wiley & Sons, Inc; 2011.
  138. Baker J. Chlorine in sewage and waste disposal. *Can Eng — Water Sew*. 2006;50:117–128.
  139. Supriyadi., Sumantri I, Hartati. I. Pengaruh Dosis Klorin Pada Pertumbuhan Bakteri Coliform Total Dan Escherichia Coli Pada Sungai Kreo, Sungai Garang Dan Sungai Tugu Suharto. *Banlit Fak Tek WAHID HASYIM SEMARANG*. 2010;12(1):30–5.
  140. Kanna CR. Inactivation of Viruses in water by chlorination using bacteriophages as model organisms . 2015;
  141. Edstrom Industries. How does UV work ? 2013;1–4.
  142. EPA. Wastewater technology fact sheet, Ultraviolet disinfection. 2009. p. 1–7.
  143. A. S, As ZA, Setiadi G. Efektivitas “Portable UV Disinfection” dalam Menurunkan Angka Bakteri (*Escherichia Coli Spp*) pada Air Minum. *J Kesehat Lingkung J dan Apl Tek Kesehat Lingkung*. 2014;11(2):223.

144. Hijnen WAM, Beerendonk EF, Medema GJ. Inactivation credit of UV radiation for viruses, bacteria and protozoan (oo)cysts in water: A review. *Water Res.* 2006;40(1):3–22.
145. Geering F. Ozone application: the state of the art in Switzerland. *Ozone Sci Eng.* 2009;21:187–200.
146. Camel V BA. The use of ozone and associated oxidation processes in drinking water treatment. 2008;32:3208–3222.
147. Staehelin J. Decomposition of ozone in water in the presence of organic solutes acting as promoters and inhibitors of radical chain reactions. *Env Sci Technol.* 2005;19:1206–1213.
148. Facile N. Evaluating bacterial aerobic spores as a surrogate for *Giardia* and *Cryptosporidium* inactivation by ozone. *Water Res.* 2010;34:3238–3246.
149. Cuthbertson C. On the Refraction and Dispersion of the Halogens, Halogen Acids, Ozone, Steam Oxides of Nitrogen, and Ammonia. 2014;213:1–26.
150. Carbon GA, Deesawasmongkol S. Advanced water treatment plant for Caboolture. *Eng Aust.* 2008;70(7):38.
151. Langlais B. *Ozone in Water Treatment, Applications and Engineering.* Chelsea, MI: Lewis Publishers. Inc; 2009. 1–10 p.
152. Wolfe R. Inactivation of *Giardia muris* and indicator organisms seeded in surface water supplies by peroxone and ozone. *Environ Sci Technol.* 2009;23:744–745.
153. Handayani L, Iryani AS. Pengaruh Kualitas Air Minum Dalam Kemasan Terhadap Konsentrasi Ozon. 2019;2006:44–51.
154. Inagaki H, Saito A, Sudaryatma PE, Sugiyama H, Okabayashi T, Fujimoto S. Rapid inactivation of SARS-CoV-2 with ozone water. *bioRxiv.* 2020;
155. Tarelluan EG, Sapulete MR, Monintja TCN. Gambaran Kualitas Air Minum Isi Ulang (Damiu) di Kelurahan Malalayang II. *J Kedokt Komunitas Dan Trop.* 2016;4(1):15–22.
156. Pracoyo NE. Penelitian bakteriologi air minum isi ulang di daerah Jabotabek. 2006;Cermin Dun:37–40.
157. Marhamah AN, Santoso B, Santoso B. Kualitas air minum isi ulang pada depot air minum di Kabupaten Manokwari Selatan. *Cassowary.* 2020;3(1):61–71.
158. Yudo S, Rahardjo PN. Evaluasi Teknologi Air Minum Isi Ulang Di Dki

- Jakarta. *J Air Indones.* 2018;1(3).
159. Macpherson C. Human behaviour and the epidemiology of parasitic zoonoses. *Int J Parasitol.* 2005;35(11-12):1319–1331.
  160. Zarlenga D. S. TJM. Concentrating, purifying and detecting waterborne parasites. *Vet Parasitol.* 2004;126(1-2):195–217.
  161. Soni S. *Microbes: A Source of Energy for 21st Century.* New India Publishing Agency; 2007.
  162. Omarova A, Tussupova K, Berndtsson R, Kalishev M, Sharapatova K. Protozoan parasites in drinking water: A system approach for improved water, sanitation and hygiene in developing countries. *Int J Environ Res Public Health.* 2018;15(3):1–18.
  163. Yaeger R. *Protozoa: Structure, Classification, Growth, and Development.* 4th ed. S B, editor. Galveston, TX, USA: University of Texas Medical Branch at Galveston; 2016.
  164. Lane S. LD. Current trends in research into the waterborne parasite *Giardia.* 2002;123–147.
  165. Baldursson S. KP. Waterborne transmission of protozoan parasites: Review of worldwide outbreaks. 2011;6603–6614.
  166. Putignani L. MD. *Global Distribution, Public Health and Clinical Impact of the Protozoan Pathogen Cryptosporidium.* 2010;
  167. Cairncross S. FR. *Environmental Health Engineering in the Tropics: An Introductory Text.* Chichester, UK: John & Wiley Sons; 2013. 283 p.
  168. S S. *Cryptosporidium and Giardia in Africa: Current and future challenges.* 2017;10:195.
  169. Huang D. An updated review on *Cryptosporidium* and *Giardia.* 2006;35:291–314.
  170. Bowers B. Comparison of pinocytosis and phagocytosis in *Acanthamoeba castellanii.* 1977. 409–417 p.
  171. Abd H., Saeed A., Weintraub A., Nair G. B. SG. *Vibrio cholerae* O1 strains are facultative intracellular bacteria, able to survive and multiply symbiotically inside the aquatic free-living amoeba *Acanthamoeba castellanii.* 2007;60(1):33–39.
  172. Imam A. M. MS. Blindness due to *Acanthamoeba*: first case report from Sudan. Sudan: *International Journal of Health Sciences (Qassim)*; 2008.

163–166 p.

173. Walia R., Montoya J. G., Visvesvera G. S., Booton G. C. DRL. A case of successful treatment of cutaneous *Acanthamoeba* infection in a lung transplant recipient. 2007;9(1):51–54.
174. Bowers, B. and EDK. The fine structure of *Acanthamoeba castellanii*. 2009;95–111.
175. Michel, R., B. Hauröder-Philippczyk, K. Müller and IW. *Acanthamoeba* from human nasal mucosa infected with an obligate intracellular parasite. 2014;30:104–10.
176. Marciano-Cabral F, Cabral G. *Acanthamoeba* spp. as agents of disease in humans. *Clin Microbiol Rev.* 2003;16(2):273–307.
177. Nwachuku N. Health Effects Support Document for *Acanthamoeba*. US EPA. 2003;
178. Schuster FL VG. Amebae and ciliated protozoa as causal agents of waterborne zoonotic disease. 2014;6(1-2):91–120.
179. Karim A. Amebiasis. 2007;20(1):33–7.
180. Haque R, Huston CD HM. Amebiasis. *N Engl J Med.* 2003;348(16):1565–73.
181. Espinosa-Cantellano M M-PA. Pathogenesis of intestinal amebiasis: from molecules to disease. *Clin Microbiol Rev.* 2010;13(2):318–31.
182. Deloer S, Nakamura R M-IF. Mouse models of amoebiasis and culture methods of amoeba. 2016;65:520–5.
183. Ximénez C, Cerritos R RL. Human Amebiasis: Breaking the Paradigm? *Int J Env Res Public Heal.* 2010;7(3):1105–20.
184. Ali I. Intestinal amebae. *Clin Lab Med.* 2015;35:393–422.
185. Nowak P, Mastalska K LJ. *Entamoeba histolytica* pathogenic protozoan of the large intestine in humans. *J Clin Microbiol Biochem Technol.* 2015;1:10–7.
186. Anaya-Velazquez FP-V. Virulence of *Entamoeba histolytica*: a challenge for human health research. 2011;6:255–8.
187. Samie, A., A Bakri, E. AbuOdeh R. Amoebiasis in the Tropics: Epidemiology and Pathogenesis. *Curr Top Trop Med.* 2012;202–226.

188. Walochnik J, Aspöck H. Protozoan Pathogens: Identification. eLS. 2006;(April).
189. Graffeo R, Archibusacci CM, Soldini S, Romano L, Masucci L. Entamoeba dispar : A Rare Case of Enteritis in a Patient Living in a Nonendemic Area . Case Rep Gastrointest Med. 2014;2014(February):1–3.
190. Lohia A. The cell cycle of Entamoeba Histolytica. 2003. 217–222 p.
191. Ayed L Ben. Entamoeba histolytica [Internet]. 2017. p. 1. Available from: <https://www.waterpathogens.org/book/entamoeba-histolytica>
192. Schuster. Opportunistic amoebae: challenges in prophylaxis and treatment. 7th ed. 2004. 41–51 p.
193. Stanley, Jr S. Amoebiasis. 361st ed. Lancet; 2013. 1025–1034 p.
194. Verweij, J.J., Oostvogel, F., Brienen, E.A.T., Nang-Beifubah, A., Ziem, J. P. Short communication: Prevalence of Entamoeba histolytica and Entamoeba dispar in northern Ghana. Trop Med Int Heal. 2013;8:1153–1156.
195. Regan, C.S., Yon, L., Hossain, M. and Elsheikha H. Prevalence of Entamoeba species in captive primates in zoological gardens in the UK. 2014;2.
196. Eichinger D. A role for a galactose lectin and its ligands during encystment of Entamoeba. J Eukaryot Microbiol. 2011;48:17–21.
197. Fraser D, Bilenko N, Deckelbaum R J, Dagan R, el-On J NL. Giardia lamblia carriage in Israeli Bedouin infants: risk factors and consequences. Clin Infect Dis. 2010;30:419–424.
198. Janovy RL dan. Foundations of Parasitology. 8th ed. New York, USA: McGraw-Hill Inc; 2009.
199. Al-Saad R, Al-Emarah G. Morphological descriptive study of giardia lamblia in man and cow at basrah. Int J Biol Res. 2014;2(2):125.
200. Karki G. Giardia lamblia: Morphology, life cycle, pathogenesis, clinical manifestation, lab diagnosis and treatment [Internet]. 2018. Available from: <https://www.onlinebiologynotes.com/giardia-lamblia-morphology-life-cycle-pathogenesis-clinical-manifestation-lab-diagnosis-and-treatment/>
201. Lujan HD. MM& N TE. Mechanism of Giardia lamblia differentiation into cyst, Microbiology and Molecular Biology Review. 2007;61:294–304.
202. Lujan HD. S. Giardia a Model Organism, 1st ed. Austria: Springer-Verlag/ Wien; 2011.

203. Fogel D, Isaac-Renton J, Guasparint R, Moorehead W, Ongerth J. Removing giardia and cryptosporidium by slow sand filtration. *J / Am Water Work Assoc.* 2013;85(11):77–84.
204. Madireddi K, Babcock RW, Levine B, Huo TL, Khan E, Ye QF, et al. Wastewater reclamation at Lake Arrowhead, California: an overview. *Water Environ Res.* 2007;69(3):350–62.
205. Al-Saad R. The Effect of chlorine on giardia cyst destruction isolated from different water sources in Maysan province. *Int J Sci World.* 2016;4(1):1.
206. USEPA. Ultraviolet Disinfection Guidance Manual. Washington DC: Office of Ground water and Drinking water; 2003. 1–3 p.
207. Burnet J.B, Penny C, Ogorzaly L CH. Spatial and temporal distribution of Cryptosporidium and Giardia in a drinking water resource: Implications for monitoring and risk assessment. 2014;472:1023–1035.
208. Fayer R, Trout J.M, Xiao L, Morgan U.M, Lal A.A DJ. Cryptosporidium canis from domestic dogs. 2001;87:1415–1422.
209. Ryan U, Fayer R XL. Cryptosporidium species in humans and animals: current understanding and research needs. *Parasitology.* 2014;141:1667–1685.
210. Fayer R. Taxonomy and species delimitation in Cryptosporidium. *Exp Parasitol.* 2010;124:90–97.
211. Xiao L RU. Cryptosporidiosis: An update in molecular epidemiology. *Curr Opin Infect Dis.* 2004;17:483–490.
212. Šlapeta J. Cryptosporidiosis and Cryptosporidium species in animals and humans: a thirty colour rainbow? *Int J Parasitol.* 2013;43:957–970.
213. Bouzid M, Hunter P.R, Chalmers R.M TK. Cryptosporidium pathogenicity and virulence. *Clin Microbiol Rev.* 2013;26:115–134.
214. O'Donoghue P. Cryptosporidium and cryptosporidiosis in man and animals. *Int J Parasitol.* 2015;25:139–195.
215. Khurana S, Chaudhary P. Laboratory diagnosis of cryptosporidiosis. *Trop Parasitol.* 2018;8(1):2–7.
216. Cacciò S.M WG. Cryptosporidium: Parasite and Disease. Germany: Springer Science & Business Media; 2013.
217. Current W RN. A comparison of endogenous development of three isolates of Cryptosporidium in suckling mice. 2016;33:98–108.



218. Tzipori S WH. Cryptosporidiosis: Biology, pathogenesis and disease. *Microbes Infect.* 2002;4:1047–1058.
219. Cotruva J.A., Durfour A., Rees G., Bartram J., Carr R., Cliver D.O., Craun G.F. FR. *Waterborne Zoonoses: Identification Causes and Control.* London, UK: IWA Publishing; 2004. 255–282 p.
220. Betancourt W.Q. RJ. Drinking water treatment processes for removal of *Cryptosporidium* and *Giardia*. 2004;126:219–234.
221. Ongerth J.E. HP. Testing of diatomaceous earth filtration for removal of *Cryptosporidium* oocysts. 2001;93:54–63.
222. Arya DDS& DP V., College DS. *Biology of Parasitism ZOOLOGY Morphology , Life Cycle , Genetic Aspects and Diagnosis of Toxoplasma gondii.* Protozoans. 5:1–17.
223. Morrison DA, Höglund J. Testing the hypothesis of recent population expansions in nematode parasites of human-associated hosts. *Heredity (Edinb).* 2005;94(4):426–34.
224. McGovern KE. Dark side illuminated: imaging of *Toxoplasma gondii* through the decades. 2013;334:6.
225. Jones JL DJ. Waterborne toxoplasmosis—recent developments. 2010;124(1):10–25.
226. Dumetre A, Le Bras C, Baffet M, Meneceur P, Dubey JP, Derouin F, Duguet JP, Joyeux M ML. Effects of ozone and ultraviolet radiation treatments on the infectivity of *Toxoplasma gondii* oocysts. 2008. :209–213.
227. Hadush A, Pal M. Ascariasis: Public Health Importance and its Status in Ethiopia. *Air Water Borne Dis.* 2016;5(1).
228. Pal M. Parasitic Zoonoses. 2014;1:1–34.
229. Holland DC; Ascaris and ascariasis. *Microbes Infect.* 2011;13:632–7.
230. Bansal R, Huang T, Chun SBansal R, Huang T CS. Trichuriasis. *Am J Med Sci.* 2018;355(2).
231. Upadhyay SK. Morphotaxonomy , Histopathology and Population Dynamics of Natural Enoplid Infections in Wild Rat , *Rattus rattus* of Eastern Uttar Pradesh , India. 2018;(December).
232. Viswanath A, Yarrarapu SNS WM. *Trichuris Trichiura* [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK507843/>

233. Gonzalez A. TAENIA SPP. Glob Water Pathog Proj. 2019;3(1):1–50.
234. Dermauw V, Dorny P, Braae UC, Devleeschauwer B, Robertson LJ, Saratsis A, et al. Epidemiology of Taenia saginata taeniosis/cysticercosis: A systematic review of the distribution in southern and eastern Africa. Parasites and Vectors. 2018;11(1):1–12.
235. Kamel ROA, Bayaamy FEZA. Ultrastructural alterations in Schistosoma mansoni juvenile and adult male worms after in vitro incubation with primaquine. Mem Inst Oswaldo Cruz. 2017;112(4):247–54.
236. Mehlhorn H, editor. Encyclopedic Reference of Parasitology. Berlin: Springer-Verlag/ Wien; 2006.
237. Nelwan ML. Schistosomiasis: Life Cycle, Diagnosis, and Control. Curr Ther Res - Clin Exp [Internet]. 2019;91(24):5–9. Available from: <https://doi.org/10.1016/j.curtheres.2019.06.001>

